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Abstract
Background: Pepsin-trypsin resistant gliadin (PT-gliadin) promotes intestinal tissue inflammation and increases
paracellular permeability of immunogenic gliadin peptides into the lamina propria. This leads to the complications
seen in the pathogenesis of celiac disease (CD). In this study, specific anti-gliadin IgY antibody was produced and
evaluated for its efficacy on gliadin induced intestinal integrity impairment and proinflammatory effects on intestinal
epithelial (Caco-2) cell culture model for CD.
Methods: Caco-2 (passages 20-24) monolayers were subjected to 7 experimental conditions (n=3 each): phosphatebuf-
feredsaline (PBS; control), pancreatic digested-casein (PD-casein; negative control), PT-gliadin (positive control), non-
specific IgY with PT-gliadin, and anti-wheat gliadin IgY with PT-gliadin at a ratio of 1:6,000, 1:3,000 and 1:1,500. Caco-2
monolayers were then evaluated for effects of gliadin and/or anti-wheat gliadin IgY after 24 h exposure. Enzyme-linked
immunosorbent assay (ELISA) was used to quantify anti-inflammatory markers (TNF-α and IL-1β) 5 days after cells were ex-
posed to PT-gliadin and/or anti-wheat gliadin IgY.
Results: Among other conditions, anti-wheat gliadin IgY at a ratio of 1:3,000 (anti-gliadin IgY: PT-gliadin) significantlypre-
vented gliadin toxicity on Caco-2 by maintaining intestinal integrity, inhibiting phenol red permeation, and inhibiting glia-
din absorption and production of proinflammatory cytokines (TNF-α and IL-1β) as compared to PT-gliadin stimulated
cultures (P < 0.05).
Conclusion: The anti-wheat gliadin IgY antibody produced in this study has proved to inhibit absorption of gliadin and
gliadin-induced inflammatory response in Caco2 cell culture model of CD. Anti-gliadin IgY, therefore has potential to
be used as an oral passive antibody therapy to treat CD.
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Background
Celiac disease is one of the most common autoimmune
diseases, occurring in 1 out of 100–300 people world-
wide [1]. CD is driven by an abnormal immune response
to the ingestion of gluten in genetically (HLA DQ2/
DQ8) predisposed individuals. Among these gluten pro-
teins, gliadin is exceptionally resistant to enzymatic deg-
radation due to its high proline and glutamine content
[2]. The PT-gliadin can cross the membrane of
enterocytes and provoke damage in a variety of ways.
Firstly, the binding of gliadin to the CXCR3 receptor re-
sults in the increased release of the protein zonulin,
which can lead to impaired mucosal integrity. Gliadin
can then enter enterocytes by transcytosis or retrotran-
scytosis via secretory IgA through the transferrin recep-
tor CD71 [3]. The release of p31–43/49 peptides triggers
the innate immune response [4], localizes to endocytic
vesicles which leads to the production of inflammatory
cytokines, such as IL-1β and TNF-α, and impaired mu-
cosal integrity [5]. P31-43 interferes with the endocytic
pathway by causing delay maturation of early endosomes
to late endosomes, thus affecting various metabolic
pathways and cellular functions [6, 7]. The 33-mer (p56-
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89) gliadin can also penetrate into the lamina propria,
triggering the T-helper cell mediated adaptive immune
response [8] that contributes to the ongoing inflamma-
tion in the small intestine of CD patients [9].
Currently, there is no pharmacological therapy avail-
able for CD patients. Only strict adherence to a GFD
helps to alleviate symptoms. Finding a more convenient,
safe, and cost-effective way of relieving symptoms would
contribute greatly to the quality of life for these patients,
and one avenue of study includes how to prevent trig-
gering the immune system upon the ingestion of gluten.
Potential therapeutic options include the hydrolysis of
toxic gliadin by exogenous enzymes [10], the modifica-
tion of gliadin-derived peptide pattern by Bifidobacteria
[8], the prevention of gliadin absorption by polymeric
binders [11], the inhibition of tight junction opening by
zonulin antagonists [12], the blockage of selective dea-
midation of specific glutamine residues by tissue tran-
glutaminase inhibitors [13], the restoration of immune
tolerance towards gluten by vaccines [14], the modula-
tion of immune response to gliadin by NKG2D/MICA
blockers [15] and the neutralization of gliadin in vivo by
IgY antibody [16].
Among these, oral passive immunotherapy may be the
best avenue to pursue simply by virtue of its advantages,
including safety, reduced cost, ease of administration, and
potential to treat localized conditions in the gastrointes-
tinal tract (GIT) [17]. Chicken egg yolk immunoglobulin
(IgY) is ideal for passive immunotherapy, as it may be
readily obtained in large quantities from egg yolk. Com-
pared to the traditional method of harvesting mammalian
antibodies, IgY purification is more cost-effective, con-
venient, and hygienic. IgY antibodies have already been
shown to be effective in neutralizing disease-causing path-
ogens such as Rotavirus [18], E. coli O157:H7 [19], Sal-
monella enteritis [20], Clostridium perfringens [21].
Despite this, there is only limited information available
that describes the use of IgY antibodies in neutralizing
toxic gliadin in an intestinal epithelium culture system.
The Caco-2 cell line has been used in several studies as an
ex vivo model of CD intestinal epithelia for initial testing
of novel CD treatment options [22–24]. In this study,
Caco-2 cell cultures were used to evaluate the effective-
ness of anti-gliadin IgY in inhibiting gliadin induced im-
paired intestinal integrity, gliadin absorption and the
inflammatory response induced by gliadin.
The objectives of this study are to produce anti-gliadin
IgY antibodies by immunizing chickens with gliadin, to
purify the resultant IgY antibodies by gel chromatog-
raphy, and to characterize its reactivity to gliadin by
western blot and ELISA techniques. The anti-gliadin IgY
antibodies were then tested for its efficacy in preventing
gliadin induced impaired intestinal integrity and inflam-
matory response in Caco-2 cell cultures.
Results
Production of anti-gliadin IgY
The anti-gliadin IgY antibodies obtained from chickens im-
munized with Sigma gliadin, wheat gliadin or PT-gliadin
were weekly titrated by indirect ELISA. As shown in Fig. 1,
the titre of anti-gliadin IgY was undetectable on day 0, rap-
idly increased (P > 0.05) from week 2 to 4, and then
remained relatively constant (P > 0.05) during week 5–7 pe-
riods. Among three gliadins, chickens produced the highest
anti-gliadin IgY in response to wheat gliadin (P > 0.05),
throughout the immunization period. Therefore, anti-
wheat gliadin IgY was used for further studies.
After 5–7 weeks of immunization, the egg yolks from
wheat gliadin immunized chickens were pooled for puri-
fication of IgY by Sephacryl S-300 gel chromatography.
The elution profile shows that fractions corresponding
to Kav 0.2–0.24 contain IgY determined by indirect
ELISA (Fig. 2). Yield of total IgY as shown in Table 1
was similar regardless of the different gliadin immuniza-
tions (P > 0.05). However, the concentration of specific
anti-gliadin IgY was significantly higher in Sigma gliadin,
wheat gliadin, and PT-gliadin immunized chickens than
in the non-immunized chickens (P < 0.05). Sephacryl S-
300 purified IgY fractions against Sigma gliadin, wheat
gliadin, and PT-gliadin contain approximately 7.9 %,
8.1 %, and 7.7 % of specific anti-gliadin IgY in a total of
IgY antibodies, respectively.
Sigma and wheat gliadins showed similar molecular
weight in the range of 30–70 kDa analyzed by SDS-
Urea-PAGE (Fig. 3a). On the other hand, the SDS-PAGE
showed that PT-gliadin contained a single peptide band
at 22 kDa. Western blot assay (Fig. 3b) was performed
to determine the anti-wheat gliadin IgY reaction to the
three gliadins. The result shows that the anti-wheat glia-
din IgY reacted with Sigma and wheat gliadins at a
range of 30–70 kDa and PT-gliadin at 22 kDa, indicat-
ing the cross-reactivity of the anti-wheat gliadin IgY to
other gliadin fragments separated by the electrophor-
esis. Another method, ELISA, was used to determine
the cross-reactivity of the anti-wheat gliadin IgY to
Sigma gliadin, PT-gliadin, barley prolamin, rye prola-
mins, oat prolamins and non-prolamin containing
grains (rice and corn). The cross reactivity was calcu-
lated based on reference to 100 % reactivity to wheat gli-
adin (OD405 = 1.152). The cross-reactivity of anti-wheat
gliadin IgY was highest to Sigma gliadin (99.3 %),
followed by barley prolamin (91.3 %), rye prolamin
(80.2 %) and oat prolamin (42.7 %). Anti-wheat gliadin
IgY also showed high cross-reactivity to PT-gliadin
(98 %), whereas the antibody cross-reactivity for non-
prolamin-containing grains was neglectable (<1 %).
Non-specific IgY, used as negative control antibody,
showed no cross reactivity to the prolamin-containing
grains mentioned above.
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IgY neutralization of toxic gliadin
To evaluate the neutralizing effect of anti-gliadin IgY on
gliadin-induced intestinal integrity deterioration, Caco-2
cells were exposed to different ratios of anti-gliadin IgY
and PT-gliadin. At 21 days, after seeding cells on the
transwell inserts, the TEER values were in the range of
305–310 Ω cm2 in well-formed Caco-2 monolayers.
Caco-2 monolayers have non-significant changes in TEER
values after 4 h in PBS, PD-casein and non-specific IgY
(control conditions) (P > 0.05). Upon 4 h exposure to PT-
gliadin there was a significant decrease in TEER value of
52 %, as compared to exposures to negative control condi-
tions in TEER value of 85 %. Basal TEER value of Caco2
monolayers at time zero is considered to have TEER value
of 100 %. When the Caco2 monolayers were exposed to
anti-gliadin IgY and PT-gliadin at a ratio of 1: 6,000 [anti-
Fig. 1 Specific IgY antibody ELISA values in the egg yolk from chickens immunized with Sigma gliadin (SG), wheat gliadin (WG), and pepsin-trypsin resistant
gliadin (PT-gliadin) (500 μg/ml protein) in PBS, emulsified with Freund’s incomplete adjuvant. Booster immunizations were given at 2 and 6 weeks after the
initial immunization. Values are the mean of quadruple samples, with vertical bars indicating the standard deviation. Arrows indicated times of immunization
Fig. 2 IgY purification by Sephacryl S-300 chromatography. Each value of absorbance was determined by an indirect ELISA. Flow rate: 3 ml/h,
Column: 1.0 × 110 cm
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gliadin IgY (10 ng) and PT-gliadin (60 μg)] for 4 h, (P >
0.05) (Fig. 4), there was no significant TEER value change.
This indicates that anti-gliadin IgY neutralized the toxic
gliadin and prevented gliadin-induced impairment of in-
testinal integrity. Anti-gliadin IgY at higher ratio (1:3,000
and 1:1,500) showed similar effects to Caco2 monolayers
exposed to anti-gliadin IgY and PT-gliadin at a ratio of 1:
6,000 (data not shown).
The monolayer integrity was determined TEER in the
range of 305–310 Ω cm2 which is mirrored by < 1 % pas-
sage of phenol red from the apical to basal chamber.
Phenol red was added to the apical chamber to deter-
mine its permeability into the basal chamber after 4 h of
exposure. Upon 4 h incubation with PBS and PD-casein
as controls, < 6 % phenol red permeated into the basal
chamber and < 10 % reduction in TEER value (Fig. 4), in-
dicating minimal disturbed intestinal integrity. After in-
cubation for 4 h with PT-gliadin, there was a significant
permeation of 28.8 % phenol red into the basal chamber
(compared to negative controls, < 6 %) and relative
TEER value of approximately 52 % (compared to nega-
tive control, 85 %) (P < 0.05). Incubation with anti-
gliadin IgY alone did not affect the intestinal integrity.
When the monolayers were exposed to three different
ratios of anti-gliadin IgY and PT-gliadin for 4 h, there
was minimal phenol red permeation of 5.0-5.6 % (P >
0.05), indicating that anti-gliadin IgY successfully pre-
vented gliadin induced impairment of intestinal integrity
at a ratio of 1:6,000.
Effect of anti-gliadin IgY on gliadin permeation in Caco2
monolayer
PT-gliadin was added to the apical chamber with/with-
out anti-gliadin IgY to determine its permeability from
the apical chamber into the basal chamber. Upon Caco-
2 monolayer exposure to PT-gliadin for 4 h, significant
decrease in Caco-2 monolayer integrity was observed,
resulting in PT-gliadin translocation of 14.8 % of total
PT-gliadin subjected to the apical chamber into the basal
chamber (P < 0.05). This is contrasted with the exposure
to three different ratios of anti-gliadin IgY and PT-
gliadin for 4 h, where the passage of gliadin into the
basal chamber was inhibited leading to undetectable
levels of PT-gliadin in the basal chamber. Table 2
showed that approximately 94 % of PT-gliadin was re-
covered in the apical chambers of monolayers exposed
to three different ratios of anti-gliadin IgY and PT-
gliadin for 4 h. However, the PT-gliadin was not de-
tected in basal chamber, indicating that the rest of glia-
din (approximately 6 %) may be located in the epithelial
cells. Thus, anti-gliadin IgY neutralized PT-gliadin in the
apical chamber, blocking gliadin absorption through the
Caco-2 monolayer.
Quantification of inflammatory markers
Figure 5 illustrates that PT-gliadin stimulated the syn-
thesis of cytokines, IL-1β and TNF-α in Caco-2 cells
after 24 h incubation. Upon PT-gliadin stimulation with
PT-gliadin incubation with anti-gliadin IgY at a ratio of
Table 1 Concentrations of protein, total IgY, and specific IgY in
purified IgY solution by Sephacryl S-300 chromatography
IgY Concentration (μg/ml) Specific IgY/
Total IgY (%)Protein Total IgY Specific IgY
Anti-Sigma gliadin 150.1 ± 1.5 136.4 ± 2.9 10.77 ± 0.05 7.9 %
Anti-wheat gliadin 152.0 ± 1.4 136.9 ± 3.3 11.05 ± 0.09 8.1 %
Anti-PT gliadin 149.0 ± 1.2 135.8 ± 3.0 10.41 ± 0.07 7.7 %
Non-specific 140.5 ± 1.7 127.5 ± 4.4 0.79 ± 0.005 0.01 %
Values are the mean of quadruple samples ± SD
Fig. 3 Gliadin fractions from Sigma: SG; Wheat: WG; and; pepsin-trypsin
digested Sigma-gliadin: PTG (10 μg/well protein) on a) Electrophoresis gel
stained with Comassie blue and; b) Western blot assay with anti-wheat
gliadin IgY
Gujral et al. BMC Immunology  (2015) 16:41 Page 4 of 11
1:6,000 [anti-gliadin IgY (10 ng) and PT-gliadin (60 μg)],
a 6.77 folds higher of TNF-α content than that of IL-1β
was detected in the Caco-2 cell culture supernatant. IL-
1β and TNF-α concentration in the cell supernatant
were significantly decreased (P < 0.05). However, other
two combinations with higher content of anti-gliadin
IgY of 1: 3,000 [anti-gliadin IgY (20 ng) and PT-gliadin
(60 μg)], and 1,500 [anti-gliadin IgY (40 ng) and PT-
gliadin (60 μg)], showed undetectable levels of TNF-α. On
the other hand, IL-1β levels remained undetectable with
all three ratios of anti-gliadin IgY co-incubations with PT-
gliadin. No cytokines were detected in cultures exposed to
control PBS, PD-casein, and non-specific IgY.
Discussion
CD is caused by the exposure of PT-gliadin containing
toxic 13-mer (p31-43) and 33-mer (p56-88) peptides [25–
27], to the intestinal lumen of genetically susceptible indi-
viduals. The PT-gliadin is absorbed from intestinal lumen
into the gut mucosa through transcellular and paracellular
means [28], causing the pathophysiologic processes in CD
and its clinical presentations.
Several therapeutic approaches have been attempted to
neutralize or prevent gliadin absorption. As this is the ini-
tial step of gliadin-induced toxicity in CD individuals, it
would prevent further damage to enterocytes. ALV003, a
mixture of glutenase and endoprotease, was reported to
enzymatically hydrolyze toxic gliadin peptides [10]. These
enzymes may hydrolyze peptides other than gliadin in the
GIT. Another candidate being extensively studied is Lara-
zotide, which inhibits zonulin, and in turn prevents toxic
gliadin peptide absorption [12]. This drug candidate
inhibits the paracellular route of gliadin absorption
through tight junctions, but would not fully inhibit
gliadin-induced damage as there are another mechanisms
of gliadin absorption, i.e. through transcellular pathways.
Fig. 4 Relative TEER and phenol red permeation measurements to determine effects of anti- gliadin IgY in Caco-2 cells. Pancreatic digested casein
(PD-casein) (60 µg); PT-gliadin (60 µg); Non-specific IgY (40 ng); Anti-gliadin IgY (10 ng) and PT-gliadin (60 µg) [1:6,000]. † indicates statistically significant
decrease in TEER value (P < 0.05). ‡ indicates statistically significant permeation of phenol red (P < 0.05). Values are shown as mean ± SD. Analysis of each
group was done in triplicates per plate. Five plates were repeated (n = 15)
Table 2 Gliadin content quantified in the apical and basal




1 h 2 h 4 h 1 h 2 h 4 h
A ND ND ND ND ND ND
C 98 ± 3 90.3 ± 3 76.3 ± 3* ND 2.5 ± 0.5 14.8 ± 1**
D ND ND ND ND ND ND
E 96.2 ± 1 93.5 ± 1 94.2 ± 1 ND ND ND
F 94.0 ± 1 93.7 ± 1 94.9 ± 1 ND ND ND
G 97 ± 1 94.9 ± 1 94.5 ± 1 ND ND ND
A: Phosphate buffered saline (PBS)
C: Pepsin-trypsin digested gliadin (PT-gliadin)
D: anti-wheat gliadin
E: PT-gliadin: anti-gliadin IgY (1:6,000)
F: PT-gliadin: anti-gliadin IgY (1:3,000)
G: PT-gliadin: anti-gliadin IgY (1:1,500)
Data from a representative experiment performed are shown as
mean ± SD (n = 15)
* indicate statistically significant lower gliadin content in apical
chamber (P < 0.05)
** indicate statistically significant higher gliadin content in basal
chamber (P < 0.05)
ND: Not detectable
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This strategy might therefore be best exploited in combin-
ation with other treatments. P(HEMA- co -SS) is another
interesting polymer reported to attenuate gliadin-induced
changes in permeability and inflammation [11]. Further in-
vestigation is required to understand the mechanisms of ac-
tion and their interaction with human tissues. All these
therapeutic candidates are promising, but further studies
are required to determine the efficacy, toxicity, and practi-
cality of such treatments. Among these, oral passive anti-
body has potential as a therapeutic option for CD.
Oral antibody passive immunotherapy is of significant
value by virtue of its advantages, including reduced cost,
ease of administration, and potential to treat localized
conditions in the GIT [17]. Several studies have exam-
ined the use of IgY against enteric pathogens such as
Salmonella enteritidis, Salmonella typhimurium [20], E.
coli O157:H7 [19], E. coli 987P [29], and Clostridium
perfringens [21]. Antibodies have the ability to bind and
sequester gliadin [30, 31], and so we used laying hens to
produce IgY specific to gliadin. The use of laying hens as
potent antibody producers has numerous advantages
over mammalian polyclonal antibody production includ-
ing the high antibody content, the relative ease of using
eggs versus serum, the low cost of animal maintenance,
and the availability of large quantities of eggs. Laying
hens usually lay about 250 eggs (approximately 4000 g
of egg yolk) in a year, compared to the serum collected
from a rabbit that is only about 40 ml. One gram of egg
yolk laid by the immunized hen contains about 10 mg of
IgY whereas 1 ml of rabbit serum yields about 35 mg of
IgG [32, 33]. The use of IgY may improve the gliadin-
binding efficacy because IgY is polyclonal, and is there-
fore able to bind to multiple epitopes on various frac-
tions of PT-gliadin. In addition, there is an economical
advantage by replacing the expensive monoclonal anti-
body with inexpensive chicken egg yolk IgY. Our previ-
ous in vivo mice feeding study has also proved that anti-
gliadin IgY prevented > 99 % gliadin absorption in the
GIT of mice fed with gliadin and anti-gliadin IgY [16].
Hence, this anti-gliadin IgY produced has potential to be
used as a therapeutic oral antibody for CD to neutralize
enzyme resistant gliadin in the GIT.
The small-bowel mucosal biopsy organ culture system
has been used extensively to clarify the pathogenesis of
CD. The advantage of the system comes from the fact that
it contains a number of different cell types so that any
element of the system can be investigated, from the epi-
thelium through to the mucosal lamina propria. CD re-
searchers have used this model to study the immune
mechanisms [4], as well as the contribution of different
cytokines [34]. Another investigative method involves bi-
opsy samples. The toxic effect of gliadin is detectable with
biopsy samples from active CD patients and short-term
treated (less than 3 years on GFD) CD patients who are
likely still to have mucosal IgA deposits present. If the CD
mucosa is taken from CD patients on GFD for > 4 years,
Fig. 5 Pro-inflammatory cytokine (IL-1β and TNF-α) in Caco-2 cell. Results are expressed as mean ± SD (n = 9). * indicates statistically significant
decrease in TNF-α production (P < 0.05)
Gujral et al. BMC Immunology  (2015) 16:41 Page 6 of 11
the biopsy samples do not secrete autoantibodies to the
supernatant due to overall absence of plasma cells and
helper T cells, as well as the failure of memory B cells to
become activated [35, 36]. This method has been widely
used in studies aiming to clarify the pathogenesis of CD,
but it is not widely used in studies related to novel treat-
ment developments. In this study, we employed Caco-2
epithelial cell instead in order to determine the ability of
anti-gliadin IgY to inhibit gliadin absorption at epithelial
level, as there is no additional benefit to use the model
with underlying celiac pathogenesis.
In literature, Caco-2 monolayers have been used to
study the inflammatory response induced by gram-
positive and -negative bacterial cell surface polysaccha-
rides, teichoic acid, protein A, peptidoglycans, lipid A-
associated proteins, lipoproteins and deoxyribonucleic
acid, to regulate cytokine synthesis [37]. Peptidoglycans,
lipoproteins, lipoteichoic acid, lipopolysaccharide, flagel-
lin and unmethylated CpG dinucleotides in bacterial
DNA are also reported to bind Toll-like receptors and
induce cytokine synthesis in Caco-2 cells [38, 39].
Caco-2 monolayers is an ideal ex vivo model of CD in-
testinal epithelium because it has been reported to pos-
sess a variety of desirable properties upon PT-gliadin
stimulation, such as decreased electrical resistance, in-
creased absorption, induced intestinal permeability [12],
exerted pro-apoptotic activity [23, 24], and stimulated
release of proinflammatory cytokines (such as TNF-α
and IL-1β), all upon PT-gliadin stimulation [5]. Caco-2
cell cultures have been employed to study the effects of
potential CD treatments, including a zonulin antagonist
(a tight junction modulator) [12], Bifidobacteria [5], ger-
minating cereal enzymes [10], and polymeric binders of
gliadin [11]. Thus, Caco-2 monolayers are an established
model used to evaluate the efficacy of anti-gliadin IgY in
neutralizing toxic gliadin at intestinal epithelium level.
However, there is also possibility of antibody effect dir-
ectly on the epithelial cells interfering mechanism of gli-
adin peptides entrance [40].
Our results show that when the apical chamber was
subjected to PT-gliadin, toxic particles flowed from the
apical compartment to the basal compartment of the
Caco-2 cultures (Table 2). However, the aforementioned
flow of peptides was inhibited in the presence of anti-
wheat-gliadin and PT-gliadin IgY co-incubated cultures.
This is particularly important because it indicates the
ability of anti-gliadin IgY to prevent the cytoskeleton re-
arrangement that promotes the intestinal permeability
that is inherent to gliadin exposure. In this context, the
minimum ratio of anti-wheat gliadin IgY and PT-gliadin
(1:6,000) contributed to maintain the intestinal barrier
integrity.
Li and colleagues have reported that there is a dra-
matic drop of Caco-2 monolayer integrity when the
culture medium was changed. This is because glutamine
was lost due to a catastrophic loss of electrical resist-
ance. As glutamine is important for intestinal barrier
function, it follows that Caco-2 monolayer integrity de-
teriorated. Membranes were able to recover after 1 h,
and it takes up to 2–4 h for protein synthesis to recover.
[41]. This is why we incubated PT-gliadin and/or anti-
gliadin IgY for 4 h to evaluate their effects on intestinal
integrity. Other researchers have reported impaired in-
testinal integrity of Caco-2 monolayers after 6 h [25],
and 3 h [12] exposure to PT-gliadin.
In the present study, PT-gliadin has also shown to
trigger the production of pro-inflammatory cytokines
(TNF-α and IL-1β), as a result of pro-inflammatory
pathways (NF-kB) activation. NF-kB is activated in the
small intestinal mucosa of CD patients [42], and gluten
peptides have been shown to upregulate the expression
of cytokines such as TNF-α [43] and IL-1β [44]. TNF-α
detected in the presence of anti-gliadin IgY with intes-
tinal digests of gliadins at a 1:6,000 ratio, demonstrated
that anti-gliadin IgY was not enough to neutralize glia-
din in the Caco-2 cell cultures. With higher IgY concen-
tration (ratio of 1:3,000), anti-gliadin IgY was able to
completely abolish the TNF-α and IL-1β production
(Fig. 5). The latter can be explained by inhibition of NF-
kB induction due to the gliadin neutralization efficacy of
anti-gliadin IgY. NF-kB (subunit proteins: p65 and p50)
is made inactive by Ik-B in the cytosol. Exposure to glia-
din prompts phosphorylation and results in destruction
of Ik-B [45]. After destruction of IkB, NF-kB enters the
nucleus and binds with DNA-activating genes that en-
code for the increased inflammatory mediators (cyto-
kines) production, leading to cellular dysfunction and
tissue destruction [46].
TNF-α together with IL-1β are the important cyto-
kines that are involved in NOS activation, both of which
act as mediators to facilitate the interaction of intrae-
pithelial lymphocytes and intestinal epithelial cells pro-
moting tissue inflammation [47]. In addition, TNF-α also
has a positive effect on attraction of neutrophils, which
cause perpetuation of inflammatory responses, cell dam-
age, and eventually epithelial barrier dysfunction [5].
There are several attempts reported in literature on treat-
ment of CD by inhibiting gliadin-induced inflammatory re-
sponses at intracellular or submucosal level, such as
zonulin antagonist [12], tissue transglutaminase inhibitors
[13], peptide vaccine [14], and NKG2D/MICA blocker [15].
In our previous study we used anti-gliadin IgY antibody
to show its inherent ability in a diagnostic role. With anti-
gliadin IgY used as capture antibody and biotinylated
mAb as detecting antibody, a highly sensitive DAS-ELISA
was developed, with linear standard range of 4–40 ng/ml
and the limit of detection equivalent to 0.8 ppm in foods
[25]. In the present study we have used anti-gliadin IgY
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antibody to establish its potential therapeutic role. The
anti-gliadin IgY antibody used in this study aims to
neutralize intestinal digests of gliadin peptides (PT-gliadin),
inhibiting gliadin-induced cytotoxic and pro-inflammatory
responses at intra-luminal level before they enter the small
intestine, ultimately preventing the gliadin induced inflam-
matory events in CD. Thus, oral administration of anti-
gliadin IgY may contribute to maintaining healthy and
normal intestine by masking ingested gliadin peptides.
However, it warrants further in vivo animal and human
studies for anti-gliadin IgY to reach its realm of CD
therapeutics.
Conclusion
In summary, the anti-wheat gliadin IgY antibody produced
in this study has proved to inhibit the absorption of glia-
din and release of gliadin-induced inflammatory response
in Caco2 cell culture model of CD. As a result, the epithe-
lial monolayer of the small intestine remains undisturbed
upon gliadin stimulation. The reported data extends the
spectrum of functional effects attributable to IgY anti-
bodies, and may provide a rationale for their potential role
in other diseases where gastrointestinal immune function
is triggered by antigens other than gliadin.
Methods
Pepsin-trypsin-gliadin (pt-gliadin) preparation
A pepsin and trypsin resistant gliadin (PT-gliadin) was
prepared according to the method previously described
with minor modifications [12]. Each 50 g Sigma gliadin
(G-3375; Sigma, St. Louis, MO) or 50 g wheat flour was
dissolved in 500 ml 0.2 N HCl for 2 h at 37 °C with 1 g
pepsin (P-7000; 800–2,500 units/mg protein, Sigma, St.
Louis, MO). The resultant peptic digest was further
digested by addition of 1 g trypsin (P-8096, activity, 4x
USP specifications; Sigma, St. Louis, MO), after pH ad-
justed to 7.4 using 2 M NaOH. The solution was stirred
vigorously at 37 °C for 4 h, boiled to inactivate enzymes
for 30 min, lyophilized, and then stored at −20 °C until
used. PT-gliadin was freshly suspended in a sterile phos-
phate buffered saline (PBS, 0.15 M NaCl, 0.0027 M KCl,
0.0081 M disodium phosphate and 0.0015 M monopo-
tassium phosphate, pH 7.2) to a final concentration of
1 mg/ml. PD-casein (BactoTryptone, Sparks, MD) was
used as a negative control in the experiment.
Production of IgY antibody
Laying hens were cared for in accordance with the guide-
lines of animal warfare of the Canadian Council on Animal
Care (CCAC 2000), approved by University of Alberta Ani-
mal Care and Use Committee (protocol AUP00000163).
Immunization of hens was carried out as previously de-
scribed [31]. Each Sigma gliadin, wheat gliadin, or PT-
gliadin (500 μg of protein/ml) was suspended in PBS
(pH 7.2) and emulsified with an equal volume of Freund’s
Incomplete Adjuvant (Sigma, St. Louis, MO). Eighteen 23-
weeks-old Single Comb White Leghorn chickens were sub-
cutaneously injected with each emulsion of Sigma gliadin
(n = 6), wheat gliadin (n = 6) or PT-gliadin (n = 6). Booster
immunizations (500 μg of protein/ml) were given after 2
and 6 weeks of the initial immunization. Eggs were col-
lected daily and stored at 4 °C until the extraction of the
antibodies.
Purification of IgY antibody
The egg yolks from hyperimmunized hens were physic-
ally separated from the egg white and first mixed gently
with eight volumes of cold distilled water (acidified with
0.1 M HCl to give pH 4.0) to avoid possible disruptions
of egg yolk granules due to the presence of high concen-
trations of acid. Cold acidified distilled water (pH 2.0)
was then added to make a final dilution of 1:10. After
mixing well, the mixture was adjusted to a pH 5.0-5.2
and incubated at 4 °C for 12 h. The WSF was obtained
by centrifugation at 3.125 x g at 4 °C for 20 min. The
supernatant was collected as the IgY rich WSF and ti-
trated by indirect ELISA (mentioned below) using Sigma
gliadin as a coating antigen. The WSF (10 mg protein/
ml) of high titre was further purified by using a 1.0 x
110 cm column of Sephacryl S-300 (GE Healthcare, Pis-
cataway, NJ) which was equilibrated and eluted with
PBS at a flow rate of 3 ml/h. Blue dextran (Pharmacia
Biotech Inc., Baie-d’Urfe, QC) and titrated water were
used to determine void volume (Vo) and total volume
(Vt) of the column, respectively. The partition coefficient
was calculated from the formula: Kav = (Ve - Vo)/(Vt -
Vo), in which Ve represents the volume of the peak frac-
tion. The eluates (1 ml) were analyzed for IgY activity at
405 nm by ELISA. The eluates of IgY were pooled,
freeze-dried and analyzed for protein content, total IgY
and specific IgY.
Quantitative ELISA for anti-gliadin IgY
Unless indicated otherwise, all incubations were performed
at 37 °C with four washes of PBS-T each step. Microtiter
plates were coated with 100 μl of rabbit anti-chicken IgG
(final concentration of 2 μg per well) or gliadin (10 mg/ml
of 60 % ethanol) for 1 h. Non-specific binding sites were
blocked with 120 μl of 3 % BSA solution (W/V) in PBS-T
for 45 min. To each well, 100 μl of of purified chicken IgG
standard, WSF (diluted 1:1,000 in PBS-T) or column frac-
tion (diluted 1:3,000 in PBS-T) was added as a specific IgY,
and non-immunized IgY prior to incubating for 1 h. Two-
fold serial dilutions of purified chicken IgG in PBS (0.5 to
0.031 μg/ml) were used as a reference antibody to prepare
a standard curve on the same plate.
Plates were subsequently added with 100 μl of rabbit
anti-chicken IgY conjugated with HRP (diluted 1:5,000 in
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PBS-T) and incubated for 90 min. After washing, 100 μl
of freshly prepared substrate solution, 2,2′-Azinobis (3-
ethylbenzothiazoline-6-sulfonic acid)-diammonium salt in
0.05 M phosphate citrate buffer (pH 5.0) containing 30 %
hydrogen peroxide was added. OD 405 nm was taken after
30 min using an ELISA Vmax kinetic microplate reader.
The ELISA value of antibody activity was determined by
subtracting the value of the control antibody from that of
specific antibody.
Preparation of Caco-2 cell culture system
Caco-2 cell culture (ATCC, Rockville, MD) was performed
as previously described [48]. Caco-2 cells (passages 20–
24) were maintained at 37 °C in (DMEM) complemented
with 4 mM glutamine, 100 U/ml penicillin, 100 U/ml
streptomycin, 1 % non-essential amino acids, 10 % heat
inactivated fetal calf serum, in an atmosphere of 90 % air
and 10 % CO2. Cells were cultured on 24-well culture
plates with polyethylene terephthalate membrane inserts
(pore size 1.0 μm; BD Bioscience, Mississauga, ON) at a
density of 3 × 105 cell/cm2. The medium was changed
three times a week and maintained for 21 days in medium
for complete differentiation.
The integrity and permeability of the monolayer was
determined by measuring the TEER value using Epithe-
lial voltohmmeter (World Precision Instrument; Haven,
CT) according to manufacturer’s instructions. The final
values were expressed as Ω × cm2 on the basis of the
following equation: TEER = (R - Rb) × A, where R is the
resistance of filter insert with cells, Rb is the resistance
of the filter alone and A is the growth area of the filter
in cm2. The transepithelial electrical resistance values
obtained in the absence of cells were considered as back-
ground measurements. All experiments were started
based on the TEER of the monolayer when it reached
300–400 Ω cm2 at 21 days after seeding cells on the
transwell inserts.
In all experiments, phenol red was included in the ap-
ical chamber to estimate paracellular diffusion through
the Caco-2 cell monolayer. The percentage of phenol
red transported into the basal chamber was calculated as
previously described [49]. Briefly, 500 μM phenol red
was subjected to the apical chamber. Aliquots of 100 μl
were removed from the basal chamber after 2 h incuba-
tion at 37 °C and added with 1 M NaOH. The OD of the
basal chamber contents was measured at 558 nm to de-
tect any leakage of the phenol red through the intercel-
lular spaces.
Neutralization experiments of IgY against PT-gliadin
Caco-2 cell culture was used to determine the PT-gliadin
neutralization effect of anti-gliadin IgY. After formation of
Caco-2 monolayer, the 24-well Caco-2 culture medium in
the basal chamber was removed and replaced with 1.2 ml
phenol red free HBSS. Caco-2 cells on the transwell in-
serts were also washed with phenol red free HBSS and re-
placed with 300 μl phenol red free HBSS. One hundred μl
of 7 different experimental conditions were added to the
wells (n = 3): A) Control: PBS; B) Negative control: PD-
casein (60 μg); C) PT-gliadin (60 μg); D) Non-specific IgY
(40 ng); E) anti-gliadin IgY (10 ng) and PT-gliadin (60 μg)
[1:6,000]; F) anti-gliadin IgY (20 ng) and PT-gliadin
(60 μg) [1:3,000]; G) anti-gliadin IgY (40 ng) and PT-
gliadin (60 μg) [1:1,500]. This experiment was repeated 5
times in different plates. After 1 h, 2 h and 4 h incubation,
the basal media were recovered, and quantified for diffu-
sion of phenol red and PT-gliadin content by measuring
the absorbance at 558 nm and ELISA, respectively. After
each experiment, the TEER values were measured in all
inserts to determine the effect on the intestinal integrity of
each experimental condition (A-G).
Quantification of gliadin
A commercially available quantitative immune-based
ELISA kit (Crystal Chem, Inc., Downers Grove, IL) was
used to quantify PT-gliadin in the apical and basal media
of the Caco-2 monolayers according to the manufac-
turer’s instructions. The analyses were performed in the
apical and basal media after 1, 2 and 4 h of incubation.
Quantification of inflammatory markers
Caco-2 cells (passages 20–24) were seeded at 50,000
cell/cm2 on 6-well plates and grown with DMEM; cul-
ture media were changed every 2 days under the condi-
tion as mentioned above. Experiments were performed
5 days post-seeding. PT-gliadin and/or anti-gliadin IgY
was exposed to cells for 24 h. Supernatants of Caco-2
cells cultures of each experimental condition was used
to quantify TNF-α (Cat no: 88–7346; eBioscience, San
Diego, CA) and human IL-1β (Cat no: 88–7010;
eBioscience, San Diego, CA) by ELISA system according
to the instruction of the manufacturers with a linear
range of 4–500 pg/ml. The results of these assays were
expressed as pg/ml of media. The experiments were per-
formed in triplicate for three times.
Statistical analysis
The data are presented as the arithmetic mean for each ex-
perimental point ± SD. For anti-gliadin IgY production, stu-
dent t-test (one-tailed t-test) was used to analyze for
significant differences (P < 0.05) between the control (non-
immunized) and samples. For cell culture study, statistical
calculations were performed using ANOVA. Differences
among 7 conditions were examined using a Turkey post
hoc test. Statistical significance at p value of 0.05 or less
was considered significant.
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